There are two scenarios in which the result of the MANO-B method could be applied to patients in the framework of the ACMG guidelines; one is for predicting the effectiveness of PARP inhibitors for patients with cancer harboring BRCA2 VUSs, and the other is for cancer risk stratification for considering prophylactic surgery to prevent cancer in patients who at the time are healthy. This evidence concerns the gene BRCA2 and cancer.